This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Breast Cancer
and you are
over 18
years old
1
2
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

This is a Phase 1b/2, multi-center, open-label, dose escalation and dose-and-schedule confirmation study of eribulin administered in combination with capecitabine.

Provided treatments

  • Drug: Eribulin mesylate administration as a 2 to 5 min IV infusion at on Day 1
  • Drug: Eribulin mesylate administration as a 2 to 5 min IV infusion on Day 1 and Day 8

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01323530. The sponsor of the trial is Eisai Limited and it is looking for 76 volunteers for the current phase.
Official trial title:
A Phase 1b/2, Multicenter,Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine